Clinical Trials Browser

OTHER × Multiple Myeloma × High-Throughput Screening Assays × Clear all

NCT03389347 2025-09-22

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Phase NA Active not recruiting

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma